Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Lancet Haematol. 2021 Aug;8(8):e562–e571. doi: 10.1016/S2352-3026(21)00170-8

Figure 1: Trial profile.

Figure 1:

HSCT =haematopoietic stem-cell transplantation. *Four patients received one cycle of brentuximab vedotin with ifosfamide, carboplatin, and etoposide; one patient received one cycle of ifosfamide, carboplatin, and etoposide; two patients received two cycles of gemcitabine, vinorelbine, and liposomal doxorubicin; and one patient received two cycles of brentuximab vedotin with bendamustine.